Vertex Pharmaceuticals Incorporated (VRTX) — Form 10-Q: Quarterly report

Vertex Pharmaceuticals Incorporated filed its quarterly report for the period ended September 30, 2026, reporting total revenues of $3.4 billion compared to $3.1 billion in the third quarter of 2025. The company completed the acquisition of Crinetics Pharmaceuticals, Inc. during the quarter, contributing to total cash, cash equivalents, and marketable securities of $9.8 billion as of September 30, 2026. Additionally, Vertex repurchased 250,543 shares of common stock under its share repurchase program during the third quarter of 2026.